Cargando…
A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960797/ https://www.ncbi.nlm.nih.gov/pubmed/27455955 http://dx.doi.org/10.1186/s12895-016-0048-z |
_version_ | 1782444589331775488 |
---|---|
author | Lee, Joo-Heung Youn, Jai-Il Kim, Tae-Yoon Choi, Jee-Ho Park, Chul-Jong Choe, Yong-Beom Song, Hae-Jun Kim, Nack-In Kim, Kwang-Joong Lee, Jeung-Hoon Yoo, Hyun-Jeong |
author_facet | Lee, Joo-Heung Youn, Jai-Il Kim, Tae-Yoon Choi, Jee-Ho Park, Chul-Jong Choe, Yong-Beom Song, Hae-Jun Kim, Nack-In Kim, Kwang-Joong Lee, Jeung-Hoon Yoo, Hyun-Jeong |
author_sort | Lee, Joo-Heung |
collection | PubMed |
description | BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis. METHODS: Sixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for 12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24. RESULTS: The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients. CONCLUSION: In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study. TRIAL REGISTRATION: This study was registered on July 7, 2009 at ClinicalTrials.gov, NCT00936065. |
format | Online Article Text |
id | pubmed-4960797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49607972016-07-27 A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis Lee, Joo-Heung Youn, Jai-Il Kim, Tae-Yoon Choi, Jee-Ho Park, Chul-Jong Choe, Yong-Beom Song, Hae-Jun Kim, Nack-In Kim, Kwang-Joong Lee, Jeung-Hoon Yoo, Hyun-Jeong BMC Dermatol Research Article BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis. METHODS: Sixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for 12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24. RESULTS: The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients. CONCLUSION: In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study. TRIAL REGISTRATION: This study was registered on July 7, 2009 at ClinicalTrials.gov, NCT00936065. BioMed Central 2016-07-25 /pmc/articles/PMC4960797/ /pubmed/27455955 http://dx.doi.org/10.1186/s12895-016-0048-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lee, Joo-Heung Youn, Jai-Il Kim, Tae-Yoon Choi, Jee-Ho Park, Chul-Jong Choe, Yong-Beom Song, Hae-Jun Kim, Nack-In Kim, Kwang-Joong Lee, Jeung-Hoon Yoo, Hyun-Jeong A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
title | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
title_full | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
title_fullStr | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
title_full_unstemmed | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
title_short | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
title_sort | multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960797/ https://www.ncbi.nlm.nih.gov/pubmed/27455955 http://dx.doi.org/10.1186/s12895-016-0048-z |
work_keys_str_mv | AT leejooheung amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT younjaiil amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT kimtaeyoon amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT choijeeho amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT parkchuljong amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT choeyongbeom amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT songhaejun amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT kimnackin amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT kimkwangjoong amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT leejeunghoon amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT yoohyunjeong amulticenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT leejooheung multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT younjaiil multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT kimtaeyoon multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT choijeeho multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT parkchuljong multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT choeyongbeom multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT songhaejun multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT kimnackin multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT kimkwangjoong multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT leejeunghoon multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis AT yoohyunjeong multicenterrandomizedopenlabelpilottrialassessingtheefficacyandsafetyofetanercept50mgtwiceweeklyfollowedbyetanercept25mgtwiceweeklythecombinationofetanercept25mgtwiceweeklyandacitretinandacitretinaloneinpatientswithmoderatetoseverepsoriasis |